Zimmer Biomet Holdings (0QQD) Price & Analysis

1 Followers

0QQD Stock Chart & Stats

CHF77.38

CHF0.00(0.00%)

At close: Jul 27 4:00 PM EDT

CHF77.38

CHF0.00(0.00%)

Day’s Range― - ―

52-Week RangeCHF77.38 - CHF77.38

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

CHF15.55B

Enterprise ValueCHF23.68K

Total Cash (Recent Filing)CHF410.00M

Total Debt (Recent Filing)CHF7.48B

Price to Earnings (P/E)24.1

Beta>-0.01

Next Earnings

Nov 04, 2026

EPS Estimate

1.5

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)4.13

Shares Outstanding190,737,690

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-1.26

Price to Book (P/B)1.40

Price to Sales (P/S)2.16

P/FCF Ratio12.09

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF85.41

Price Target Upside10.38% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering18

EPS Forecast (FY)6.83

Revenue Forecast (FY)CHF6.88B

Bulls Say, Bears Say

Bulls Say

Strong Cash GenerationImproving operating cash flow and free cash flow provide durable funding for research, manufacturing capacity, acquisitions and shareholder returns, reducing reliance on external financing while supporting strategic flexibility.

Technology And Hip AdoptionStrong adoption of hip implants, robotics and surgical-enabling products can deepen surgeon relationships, increase procedural content and improve Zimmer Biomet's competitive position in technology-led orthopedic care.

Broad Product InnovationA substantial product pipeline and differentiated offerings support future revenue opportunities across orthopedic procedures. Continued innovation can refresh the portfolio, address clinical needs and defend market share over multiple years.

Bears Say

Sustained Margin PressureInvestment in the U.S. commercial organization and higher manufacturing costs are compressing profitability. If these costs persist longer than productivity gains, weaker operating leverage could limit earnings and cash-flow growth.

Pricing And Reimbursement RiskImplant pricing pressure and reimbursement changes can structurally reduce revenue per procedure and gross margins. These risks may intensify competitive pressure and make it harder for innovation and mix improvements to offset erosion.

Knee And China WeaknessKnees remain a core reconstructive category, so weak performance in that franchise can weigh on portfolio growth. China and emerging-market weakness also limits geographic diversification and may prolong difficult comparisons.

Zimmer Biomet Holdings News

Zimmer Biomet price target raised to $100 from $83 at Canaccord

Canaccord analyst Caitlin Cronin raised the firm’s price target on Zimmer Biomet (ZBH) to $100 from $83 and...

18d ago

ZBH

Zimmer Biomet price target raised to $106 from $92 at Truist

Truist raised the firm’s price target on Zimmer Biomet (ZBH) to $106 from $92 and keeps a Hold...

21d ago

ZBH

Zimmer Biomet price target raised to $106 from $92 at Truist

Truist raised the firm’s price target on Zimmer Biomet (ZBH) to $106 from $92 and keeps a Hold...

22d ago

ZBH

Zimmer Biomet price target raised to $104 from $92 at Baird

Baird raised the firm’s price target on Zimmer Biomet (ZBH) to $104 from $92 and keeps a Neutral...

22d ago

ZBH

Zimmer Biomet price target raised to $98 from $88 at Deutsche Bank

Deutsche Bank raised the firm’s price target on Zimmer Biomet (ZBH) to $98 from $88 and keeps a...

22d ago

ZBH

Zimmer Biomet price target raised to $120 from $115 at UBS

UBS analyst Patrick Wood raised the firm’s price target on Zimmer Biomet (ZBH) to $120 from $115 and...

22d ago

ZBH

Zimmer Biomet price target raised to $110 from $105 at Stifel

Stifel analyst Rick Wise raised the firm’s price target on Zimmer Biomet (ZBH) to $110 from $105 and...

22d ago

ZBH

Zimmer Biomet price target raised to $93 from $91 at Bernstein

Bernstein raised the firm’s price target on Zimmer Biomet (ZBH) to $93 from $91 and keeps a Market...

22d ago

ZBH

Zimmer Biomet price target raised to $96 from $95 at BMO Capital

BMO Capital raised the firm’s price target on Zimmer Biomet (ZBH) to $96 from $95 and keeps a...

22d ago

ZBH

Zimmer Biomet price target raised to $110 from $101 at RBC Capital

RBC Capital analyst Kendall Au raised the firm’s price target on Zimmer Biomet (ZBH) to $110 from $101...

22d ago

ZBH

Zimmer Biomet Raises Outlook Amid Transition Year

Zimmer Biomet Holdings (($ZBH)) has held its Q2 earnings call. Read on for the main highlights of the...

18d ago

ZBH

Zimmer Biomet updates segment reporting and disclosures

Zimmer Biomet Holdings ( ($ZBH) ) just unveiled an announcement. In the quarter ended March 31, 2026, Zimmer...

23d ago

ZBH

Zimmer Biomet Holdings (ZBH) Q2 Earnings Cheat Sheet

Zimmer Biomet Holdings (ZBH) is scheduled to report 2nd quarter earnings on 08/05/2026, before the market opens. Regarding...

26d ago

ZBH

Zimmer Biomet: Solid Orthopedics Franchise and Early-Stage Digital Investments Support Neutral Risk-Reward, Justifying Hold Rating

BTIG analyst Ryan Zimmerman has maintained their neutral stance on ZBH stock, giving a Hold rating on July...

1M ago

ZBH

0QQD FAQ

What was Zimmer Biomet Holdings’s price range in the past 12 months?

Zimmer Biomet Holdings lowest share price was CHF77.38 and its highest was CHF77.38 in the past 12 months.

What is Zimmer Biomet Holdings’s market cap?

Zimmer Biomet Holdings’s market cap is CHF15.55B.

When is Zimmer Biomet Holdings’s upcoming earnings report date?

Zimmer Biomet Holdings’s upcoming earnings report date is Nov 04, 2026 which is in 68 days.

How were Zimmer Biomet Holdings’s earnings last quarter?

Zimmer Biomet Holdings released its earnings results on Aug 05, 2026. The company reported CHF1.654 earnings per share for the quarter, beating the consensus estimate of CHF1.606 by CHF0.048.

Is Zimmer Biomet Holdings overvalued?

According to Wall Street analysts Zimmer Biomet Holdings’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Zimmer Biomet Holdings pay dividends?

Zimmer Biomet Holdings does not currently pay dividends.

What is Zimmer Biomet Holdings’s EPS estimate?

Zimmer Biomet Holdings’s EPS estimate is 1.5.

How many shares outstanding does Zimmer Biomet Holdings have?

Zimmer Biomet Holdings has 190,737,690 shares outstanding.

What happened to Zimmer Biomet Holdings’s price movement after its last earnings report?

Zimmer Biomet Holdings reported an EPS of CHF1.654 in its last earnings report, beating expectations of CHF1.606. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Zimmer Biomet Holdings?

Currently, no hedge funds are holding shares in GB:0QQD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Zimmer Biomet Holdings Stock Smart Score

Neutral

Fundamentals

Return on Equity

1.06%

Trailing 12-Months

Asset Growth

-0.29%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

Zimmer Biomet Holdings (0QQD) Earnings & Revenues

Historic Earnings Reports

0QQD Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveyed multiple strong operational and financial positives — revenue beat, raised guidance, robust cash generation, rapid technology and hip product adoption, successful Paragon integration and a sizable buyback — while acknowledging near-term headwinds including margin pressure from investment and manufacturing costs, pricing erosion risk, weakness in knees and China, and some supply constraints. Management framed 2026 as a transitional year with confidence that investments and go-to-market changes will improve execution and performance into 2027.View all GB:0QQD earnings summaries

0QQD Net sales Breakdown

40.36% Knees

25.43% Hips

26.12% S.E.T

8.09% Technology & Data, Bone Cement and Surgical

0QQD Stock 12 Month Forecast

Average Price Target

CHF85.41

▲(10.38% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"73":"CHF73","79":"CHF79","85":"CHF85","91":"CHF91","97":"CHF97"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":96.6294048,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF96.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":85.40965724266665,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF85.41</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":74.88778872,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF74.89</span>\n  </div></div>","useHTML":true}}],"tickPositions":[73,79,85,91,97],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,77.376,78.85703113846154,80.33806227692308,81.81909341538461,83.30012455384616,84.78115569230769,86.26218683076924,87.74321796923077,89.22424910769232,90.70528024615385,92.1863113846154,93.66734252307693,95.14837366153847,{"y":96.6294048,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,77.376,77.99397363405129,78.61194726810257,79.22992090215385,79.84789453620513,80.46586817025641,81.0838418043077,81.70181543835896,82.31978907241025,82.93776270646153,83.55573634051281,84.17370997456409,84.79168360861537,{"y":85.40965724266665,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,77.376,77.1845991323077,76.99319826461539,76.80179739692308,76.61039652923077,76.41899566153846,76.22759479384615,76.03619392615386,75.84479305846155,75.65339219076924,75.46199132307693,75.27059045538462,75.07918958769231,{"y":74.88778872,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":77.376,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.376,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.376,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.376,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.376,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.376,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.376,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.376,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.376,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.376,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.376,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.376,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.376,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >